# OnCo record kras-g12c-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/kras-g12c-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "kras-g12c-pdac" ;
  schema:name "KRAS G12C-mutant pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "KRAS G12C pancreatic cancer"@en, "KRAS p.G12C PDAC"@en, "G12C-mutant pancreatic adenocarcinoma"@en ;
  schema:description "KRAS G12C pancreatic cancer is the small slice of pancreatic cancer whose KRAS mutation happens to be the one that the first KRAS drugs were built for. Sotorasib and adagrasib, approved for lung cancer, shrink a share of these tumours after chemotherapy and are listed as options, and newer inhibitors such as elironrasib, olomorasib and the pan-RAS drug daraxonrasib are being tested in this group."@en ;
  schema:url <https://onco.cc/cancers/kras-g12c-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/KRAS> ;
  schema:citation <https://en.wikipedia.org/wiki/KRAS>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/kras-g12c-nsclc/>, <https://onco.cc/cancers/kras-g12c-colorectal/>, <https://onco.cc/roadmaps/kras-roadmap/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/garsorasib/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> ;
  onco:companies <https://onco.cc/companies/amgen/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/jacobio-pharmaceuticals/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/oncogene/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/ca19-9/> ;
  onco:trials <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/nct06128551/>, <https://onco.cc/trials/nct04956640/>, <https://onco.cc/trials/nct06008288/>, <https://onco.cc/trials/nct06244771/>, <https://onco.cc/trials/nct07491445/> ;
  onco:people <https://onco.cc/people/kevan-shokat/>, <https://onco.cc/people/frank-mccormick/>, <https://onco.cc/people/tanios-bekaii-saab/>, <https://onco.cc/people/eileen-oreilly/>, <https://onco.cc/people/andrew-aguirre/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/>, <https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/> ;
  onco:pipeline <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/trials/nct06128551/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/nct04956640/>, <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/trials/nct06008288/>, <https://onco.cc/drugs/divarasib/>, <https://onco.cc/drugs/garsorasib/>, <https://onco.cc/trials/nct06244771/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/trials/nct07491445/> ;
  onco:standardOfCare <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/trials/nct06128551/>, <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/trials/nct04956640/>, <https://onco.cc/drugs/glecirasib/>, <https://onco.cc/trials/nct06008288/> .